Company Encyclopedia
View More
name
Sanbo
301293.SZ
Sanbo Hospital Management Group Limited, together with its subsidiaries, engages in hospital management in China. The company operates neurology and general hospitals. It is also involved in clinical medical; medical device management; medical investment; and property management services. Sanbo Hospital Management Group Limited was founded in 2003 and is headquartered in Beijing, China.
173.94 B
301293.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care FacilitiesIndustry
Industry Ranking2/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.63%C
    • Profit Margin5.12%C
    • Gross Margin22.72%D
  • Growth ScoreB
    • Revenue YoY16.75%B
    • Net Profit YoY-23.29%D
    • Total Assets YoY24.85%A
    • Net Assets YoY5.23%B
  • Cash ScoreB
    • Cash Flow Margin1954.56%A
    • OCF YoY16.75%B
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreB
    • Gearing Ratio29.57%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sanbo Neuroscience released its performance for the first three quarters, with a net profit attributable to the parent company of 83.6282 million yuan, a decrease of 20.01%

    Sanbo Neuroscience released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 1.273 billion yuan, a year-on-year increase of 20.26%. The net profit attributable to the parent company was 83.6282 million yuan, a year-on-year decrease of 20.01%; the net profit after deducting non-recurring gains and losses was 84.9638 million yuan, a year-on-year decrease of 4.85%. The basic earnings per share were 0.41 yuan

    Zhitong·
    SZ
    301293
    +1.39%
    Zhitong·
    SZ
    301293
    +1.39%

    Sanbo: The company's brain-computer interface is still in the experimental development and laboratory validation stage

    On September 24th, Sanbo stated on the interactive platform that the company's brain-computer interface is still in the experimental development and laboratory validation stage, and there is still a series of validation processes before it can be maturely applied. Currently, it will not have a significant impact on the company

    Zhitong·
    SZ
    301293
    +1.39%
    Zhitong·
    SZ
    301293
    +1.39%

    Sanbo Neuroscience plans to participate in the investment to establish Tianjin Yuanming Haihe Brain Science Venture Capital Partnership

    Sanbo announced that it will participate as a limited partner in the establishment of Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, planning to raise funds of 300 million yuan, with the company subscribing 57 million yuan of its own funds. This move aims to improve the industrial chain, enhance clinical diagnosis and treatment levels, and focus on investments in the field of brain science, particularly in the areas of brain disease examination, treatment, and health management, to strengthen the company's competitiveness

    Zhitong·
    SZ
    301293
    +1.39%
    Zhitong·
    SZ
    301293
    +1.39%

    Brain-computer interface concept stocks fell at the beginning of trading, Innovative Medical hit the limit down

    Brain-computer interface concept stocks fell at the beginning of trading, Innovative Medical hit the limit down, Stonehill Technology dropped over 7%, Aiteng Medical, Sanbo, and Jihua Group all declined

    Zhitong·
    SZ
    301293
    +1.39%
    SH
    601718
    +2.05%
    SZ
    002195
    +2.04%
    Zhitong·
    SZ
    301293
    +1.39%
    SH
    601718
    +2.05%
    SZ
    002195
    +2.04%

    Sanbo: In the first half of 2025, the net profit was 69.6957 million yuan, a year-on-year increase of 4.60%

    Sanbo announced that in the first half of 2025, operating revenue was 827 million yuan, a year-on-year increase of 17.54%. Net profit was 69.6957 million yuan, a year-on-year increase of 4.60%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

    Zhitong·
    SZ
    301293
    +1.39%
    Zhitong·
    SZ
    301293
    +1.39%
    © 2025 Longbridge｜Disclaimer